Skip to main content

Pulmonary Embolism in a Young Immunocompetent Adult Infected with Cytomegalovirus. Are Novel Oral Anticoagulants an Efficient Alternative?

Publication ,  Journal Article
Bountouris, I; Moris, D; Tsilimigras, DI; Laoutaris, G; Kritikou, G; Palla, V-V; Karaolanis, G
Published in: In vivo (Athens, Greece)
November 2017

Cytomegalovirus (CMV) infection is a common disease especially in young adults. Thromboembolism like deep vein thrombosis and pulmonary embolism is increased among patients with CMV infection. Most cases represent immunocompromised patients usually treated with low molecular weight heparin.Herein, we describe a 25-year-old immunocompetent male who presented at the emergency department with sudden onset of chest pain. One month prior to admission, he had developed persistent fever and cough and the diagnosis of CMV infection had been established. After extensive workup, the diagnosis of pulmonary embolism after CMV infection was set and he was treated with rivaroxaban. During the next six months the patient continued on the same anticoagulant therapy with no other episode of pulmonary embolism at 1-year follow-up.To our knowledge, this is the first case of CMV-associated pulmonary embolism treated with novel oral anticoagulants (NOACs). NOACs, such as rivaroxaban, seem to be safe and may represent an attractive alternative with promising results in this particular group of patients. Studies incorporating a greater cohort of patients are needed in order to draw safe conclusions regarding the relationship between NOACs and CMV infection.

Duke Scholars

Published In

In vivo (Athens, Greece)

DOI

EISSN

1791-7549

ISSN

0258-851X

Publication Date

November 2017

Volume

31

Issue

6

Start / End Page

1193 / 1195

Related Subject Headings

  • Rivaroxaban
  • Pulmonary Embolism
  • Oncology & Carcinogenesis
  • Male
  • Immunocompromised Host
  • Humans
  • Cytomegalovirus Infections
  • Cytomegalovirus
  • Anticoagulants
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bountouris, I., Moris, D., Tsilimigras, D. I., Laoutaris, G., Kritikou, G., Palla, V.-V., & Karaolanis, G. (2017). Pulmonary Embolism in a Young Immunocompetent Adult Infected with Cytomegalovirus. Are Novel Oral Anticoagulants an Efficient Alternative? In Vivo (Athens, Greece), 31(6), 1193–1195. https://doi.org/10.21873/invivo.11189
Bountouris, Ioannis, Demetrios Moris, Diamantis I. Tsilimigras, George Laoutaris, Georgia Kritikou, Viktoria-Varvara Palla, and Georgios Karaolanis. “Pulmonary Embolism in a Young Immunocompetent Adult Infected with Cytomegalovirus. Are Novel Oral Anticoagulants an Efficient Alternative?In Vivo (Athens, Greece) 31, no. 6 (November 2017): 1193–95. https://doi.org/10.21873/invivo.11189.
Bountouris I, Moris D, Tsilimigras DI, Laoutaris G, Kritikou G, Palla V-V, et al. Pulmonary Embolism in a Young Immunocompetent Adult Infected with Cytomegalovirus. Are Novel Oral Anticoagulants an Efficient Alternative? In vivo (Athens, Greece). 2017 Nov;31(6):1193–5.
Bountouris, Ioannis, et al. “Pulmonary Embolism in a Young Immunocompetent Adult Infected with Cytomegalovirus. Are Novel Oral Anticoagulants an Efficient Alternative?In Vivo (Athens, Greece), vol. 31, no. 6, Nov. 2017, pp. 1193–95. Epmc, doi:10.21873/invivo.11189.
Bountouris I, Moris D, Tsilimigras DI, Laoutaris G, Kritikou G, Palla V-V, Karaolanis G. Pulmonary Embolism in a Young Immunocompetent Adult Infected with Cytomegalovirus. Are Novel Oral Anticoagulants an Efficient Alternative? In vivo (Athens, Greece). 2017 Nov;31(6):1193–1195.

Published In

In vivo (Athens, Greece)

DOI

EISSN

1791-7549

ISSN

0258-851X

Publication Date

November 2017

Volume

31

Issue

6

Start / End Page

1193 / 1195

Related Subject Headings

  • Rivaroxaban
  • Pulmonary Embolism
  • Oncology & Carcinogenesis
  • Male
  • Immunocompromised Host
  • Humans
  • Cytomegalovirus Infections
  • Cytomegalovirus
  • Anticoagulants
  • Adult